Accelovance Continues Expansion with Opening of Research Triangle Park, North Carolina Office
Accelovance announced the opening of a new office in Research Triangle Park, North Carolina.
Accelovance, a therapeutically focused clinical research organization (CRO), announced today the opening of a new office in Research Triangle Park (RTP), North Carolina. This office opening supports continued corporate expansion and provides Accelovance's clients and employees with a presence in the research-active landscape of the RTP area of North Carolina. The new offices are close to many current and potential clients and offer a rich base of technical talent to support continued corporate growth.
"Building and scaling a high-quality team is a key driver to our continued success as a business," said Stephen Trevisan, President and CEO. "RTP was one of our top choices as a location, since it offers an excellent talent pool of research professionals who have the experience to help us better serve our customers."
Accelovance plans to add up to 15 new clinical operations positions in the RTP area this year.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
